Angiogenesis is necessary for growth and progression of injury of primary tumors and their metastases. Angiogenesis inhibitors discovered in this Program Project are in clinical trials, and the prognostic value of microvessel density in tumors is used in many medical centers. In the renewal of this Program Project, 7 investigators who work closely together, and whose laboratories are all on the same floor, will study the regulation of angiogenesis at the molecular and cellular levels and in tumor-bearing animals. Vascular endothelial growth factor (VEGF), produced by the majority of human tumors, will be investigated by characterization of a novel VEGF receptor and development of receptor neutralizing reagents (Klagsbrun). Vascular development and differentiation will be investigated by studying the role of specific VEGF isoforms, and by characterization of a novel gene which may be involved in endothelial differentiation (D'Amore). Mechanisms through which tissue inhibitors of metalloproteinases (TIMP) exert their anti-angiogenic effects will be studied by characterizing shifts in proteolytic balance in tumor cells and by functional analysis of different structural domains of the TIMPS (Moses). Focal adhesion complexes (FAC) between vascular endothelial cells (EC) and their extracellular matrix will be studied to determine how information is transmitted to the nucleus and how this is affected by angiogenesis inhibitors that are in clinical or pre-clinical application (Ingber). E-selectin, which is expressed in proliferating EC in angiogenic tissues, will be studied to determine the pathways for its up-regulation, to determine the stimulators and inhibitors inhibit, the motility of EC during angiogenesis will be studied (Zetter). A powerful new antiangiogenic protein, endostatin, will be produced in E.coli and used to regress human and animal tumor dormancy in mice, a model which closely resembles human tumor dormancy, will be investigated. Pre-clinical studies of """"""""dormancy therapy"""""""" will be conducted (Folkman). The studies in this Program Project all focus on the development of a detailed understanding of the angiogenic process with the goal of applying this knowledge to current and future clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA045548-12
Application #
2683467
Study Section
Subcommittee G - Education (NCI)
Program Officer
Freeman, Colette S
Project Start
1987-09-01
Project End
2002-03-31
Budget Start
1998-04-01
Budget End
1999-03-31
Support Year
12
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Adapala, R K; Thoppil, R J; Ghosh, K et al. (2016) Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy. Oncogene 35:314-22
Pelton, Kristine; Coticchia, Christine M; Curatolo, Adam S et al. (2014) Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol 184:2099-110
German, Alexandra E; Mammoto, Tadanori; Jiang, Elisabeth et al. (2014) Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. J Cell Sci 127:1672-83
Ingber, Donald E; Wang, Ning; Stamenovic, Dimitrije (2014) Tensegrity, cellular biophysics, and the mechanics of living systems. Rep Prog Phys 77:046603
Roy, R; Zurakowski, D; Wischhusen, J et al. (2014) Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer 111:1772-9
Procaccia, Vera; Nakayama, Hironao; Shimizu, Akio et al. (2014) Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility. Biochem Biophys Res Commun 448:134-8
Battinelli, Elisabeth M; Markens, Beth A; Kulenthirarajan, Rajesh A et al. (2014) Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 123:101-12
Li, Wenliang; Ai, Nanping; Wang, Suming et al. (2014) GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci U S A 111:1521-6
Yang, Jiang; McNeish, Brendan; Butterfield, Catherine et al. (2013) Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 27:45-50
Zaslavsky, Alexander; Chou, Stella T; Schadler, Keri et al. (2013) The calcineurin-NFAT pathway negatively regulates megakaryopoiesis. Blood 121:3205-15

Showing the most recent 10 out of 277 publications